Mandate

Vinge advises international private equity firm Cinven on the acquisition of Envirotainer

July 12, 2018 M&A

Headquartered in Stockholm, Envirotainer designs, manufactures and leases active temperature-controlled containers used primarily for air freighting biopharma products, transporting up to two millions doses of medicine per day. Envirotainer serves c. 600 customers worldwide, including many of the blue-chip global biopharma companies.

With c. 300 employees, Envirotainer operates from regional centres in Stockholm, Frankfurt, Dallas and Singapore, with a portfolio of more than 5,500 leased containers globally. Envirotainer developed and marketed the first container with an active temperature control system in 1995 and since then has significantly invested in technology and its container fleet.

Vinge’s team consisted of partners Christina Kokko and Kristina Ekberg (M&A), Louise Brorsson Salomon and Albert Wållgren (Banking and Finance) together with associates Filip Öhrner, Samra Baytar, Karl Klackenberg, Anna Thoms, Vilhelm Rondahl and Arvid Axelryd (M&A), Linn Adelwald and Agnes Perbo (Banking and Finance), Hedvig Ekdahl, Lisa Hörnqvist and Hayaat Ibrahim (Commercial Agreements), Klara Secher (IP), Sara Strandberg and Sophia Holm (Employment), Johan Cederblad (Environment), Frida Ställborn (Real Estate) and VDR assistant Jessica Öijer.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025